Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Context: The RAF inhibitor vemurafenib has provided a major advance for the treatment of patients with BRAF-mutant metastatic melanoma. However, BRAF-mutant thyroid cancer is relatively resistant to vemurafenib, and the reason for this disparity remains unclear. Anticancer therapy-induced autophagy can trigger adaptive drug resistance in a variety of cancer types and treatments. To date, role of autophagy during BRAF inhibition in thyroid cancer remains unknown. Objective: In this study, we investigate if autophagy is activated in vemurafenib-treated BRAF-mutant thyroid cancer cells, and whether autophagy inhibition improves or impairs the treatment efficacy of vemurafenib. Design: Autophagy level was determined by western blot assay and transmission electron microscopy. The combined effects of autophagy inhibitor and vemurafenib were assessed in terms of cell viability in vitro and tumor growth rate in vivo. Whether the endoplasmic reticulum (ER) stress was in response to vemurafenib-induced autophagy was also analyzed. Results: Vemurafenib induced a high level of autophagy in BRAF-mutant thyroid cancer cells. Inhibition of autophagy by either a pharmacological inhibitor or interfering RNA knockdown of essential autophagy genes augmented vemurafenib-induced cell death. Vemurafenib-induced autophagy was independent of MAPK signaling pathway and was mediated through the ER stress response. Finally, administration of vemurafenib with the autophagy inhibitor hydroxychloroquine promoted more pronounced tumor suppression in vivo. Conclusions: Our data demonstrate that vemurafenib induces ER stress response-mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Rabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563 · cited 1×
“Fagin (Memorial Sloan–Kettering Cancer Institute, New York, New York) and was authenticated using short tandem repeat- and singlenucleotide polymorphism array analysis (23).”
MethodTargeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma
Ma, X.-H., Piao, S.-F., Dey, S., Mcafee, Q., Karakousis, G., Villanueva, J., Hart, L. S., Levi, S., Hu, J., Zhang, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70454 · Cited by 457
Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382
Kondo, Y., & Kondo, S. (2006) · Autophagy · doi:10.4161/auto.2.2.2463 · Cited by 305 · cited 1×
“The MAPK pathway is 1 of the signaling pathways that regulates autophagy in mammalian cells (28).”
BackgroundLazova, R., Camp, R. L., Klump, V., Siddiqui, S. F., Amaravadi, R. K., & Pawelek, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1282 · Cited by 305 · cited 1×
“Autophagy can facilitate removal of proteins or organelles that are damaged by drug treatment in cancer cells, and provide fuel for cancer cells from the degraded cellular components (16, 17).”
BackgroundMa, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2372 · Cited by 234
Cited by
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“320,538 Therapeutics success beyond autophagy targeted RAFi therapy .”
BackgroundAutophagy in tumour immunity and therapy
Xia, H., Green, D. R., & Zou, W. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00344-2 · Cited by 404
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Monitoring autophagy in cancer: From bench to bedside
Long, M., & McWilliams, T. G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.016 · Cited by 30
Metadata
- Authors
- Wang, W., Kang, H., Zhao, Y., Min, I., Wyrwas, B., Moore, M., Teng, L., Zarnegar, R., Jiang, X., & Fahey, T. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-10-18
- Volume
- 102
- Issue
- 2
- Pages
- 634-643
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2533268283
- Cited by
- 68
- References
- 9
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. https://app.cochat.ai/papers/10.1210/jc.2016-1999
- The paper
- Wang, W., Kang, H., Zhao, Y., Min, I., Wyrwas, B., Moore, M., Teng, L., Zarnegar, R., Jiang, X., & Fahey, T. J. (2017). Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2016-1999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.